SPRY
ARS Pharmaceuticals, Inc
4.30$
+5.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | -1,455.8% | -699.6% | 48.5% | -511.0% | -251.9% | -144.8% | -154.8% | -198.2% | -181.0% | -168.0% | |
| – | – | – | 3.6% | 1.0% | -1.7% | -21.1% | 1.8% | 7.2% | -5.5% | 1.8% | 1.2% | 1.4% | |
| – | – | – | 673.0% | 173.6% | 4.9% | 66.4% | 34.2% | 17.5% | 20.4% | 32.7% | 36.8% | 26.7% | |
| – | – | – | 751.6% | -70.8% | -12.3% | -130.7% | -6.7% | -3.3% | -26.6% | 37.9% | -38.1% | -10.9% | |
| – | – | – | 7.6% | 6.8% | 0.3% | 1.1% | 0.3% | 0.6% | 0.0% | 0.0% | 0.0% | 0.2% | |
| – | – | – | -2,529.2% | 813.2% | -117.5% | 364.5% | 309.0% | -138.4% | 85.9% | 122.5% | 123.5% | 41.5% | |
| – | – | – | – | – | – | – | – | – | -2.6% | – | – | – | |
| – | – | – | 109.0% | 32.9% | 81.9% | 9.1% | 17.2% | 307.8% | 4.0% | 0.7% | 9.5% | 89.4% | |
| – | – | – | -3,876.0% | 146.6% | 12.9% | -137.4% | 74.3% | 24.7% | -64.9% | -74.9% | -48.0% | -37.1% | |
| – | – | – | -1,463.4% | -706.3% | 48.2% | -512.1% | -252.2% | -145.4% | -154.8% | -198.2% | -181.0% | -168.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.